E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Allergic Rhinitis
Asthma |
Allergische rinitis
Astma |
|
E.1.1.1 | Medical condition in easily understood language |
Hay fever and asthma |
hooikoorts en astma |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
It has been suggested that adequate treatment of AR might be beneficial for the lower airways. Whereas INCS and perhaps antihistamines may be a promising additive treatment to reduce asthma symptoms in patients with rhinitis and mild asthma, more research is needed.
This study consists of two research questions:
Which treatment (antihistamines/INCS on demand/INCS continuously) is most effective in children with AR due to pollen allergy under treatment by the general practitioner?
What is the effectiveness of AR treatment on asthma symptoms and asthma control in patients with AR and concomitant asthma?
|
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Children aged 6-18 years
- Recruitment in general practice based on doctor’s diagnosis AR (ICPC R97) or prescription of allergy medication (antihistamines, INCS) in the last year.
- Sensitization to grass pollen or grass and tree pollen (determined by CAP-RAST, class >= 2).
- Present symptoms of allergic rhinitis and conjunctivitis. Severity will be determined by a retrospective symptom score (patients have to recall their complaints during the previous hay fever season). Seven complaints of nose (sneezing, nose blockage, runny nose, itching nose) and eye (itching eyes, redness and tearing eyes), will be determined. Each symptom is recorded on a scale from 0 to 3. A minimum of 7 out of the maximum of 21 points is required to be included in the study.
- Informed consent
|
|
E.4 | Principal exclusion criteria |
- Use of INCS one month prior to randomization or antihistamines one week prior to randomization
- Currently pregnant or breastfeeding
- Spending a significant amount of time abroad during the study period
- Not able to speak and understand the Dutch language sufficiently
- Not having internet access to fill in the diary and questionnaires
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Research Question 1.
Percentage of (nose and eye) symptom free days during the tree and/or grass pollen season.
Research Question 2.
Asthma control. |
Onderzoeksvraag 1.
Percentage van (neus en oog) symptoom vrije dagen gedurende 3 maanden in het boompollen / graspollen seizoen.
Onderzoeksvraag 2.
Astma controle. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Daily for diary questions or monthly for questionnaires |
Dagelijks voor dagboek en maandelijks voor vragenlijst |
|
E.5.2 | Secondary end point(s) |
Allergy symptom score, (rescue)medication free days, AR-specific quality of life, patient’s preference of medication.
Outcomes regarding the effectiveness of AR-treatment on asthma: % days without asthma symptoms, asthma symptom score, asthma medication free days, asthma quality of life, and degree of asthma control.
|
Allergie symptoomscore, (rescue)medicatie vrije dagen, AR-specifieke kwaliteit van leven, patiënten voorkeur voor medicatie.
Uitkomstmaten met betrekking tot AR-behandeling op astma: % dagen zonder astma symptomen, astma symptoomscore, astma medicatie vrije dagen, astma-specifieke kwaliteit van leven, mate van astma controle.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Daily for diary questions or monthly for questionnaires |
Dagelijks voor dagboek en maandelijks voor vragenlijst |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | 0 |